Preclinical Programs

The generation of ActoGeniX’ preclinical product pipeline is based on two lines of research. First, protein therapeutics targeting local mucosal, submucosal and luminal targets in the gut. Secondly, antigen-derived peptides targeting the immune system in the gut and inducing a state of tolerance towards these antigens.

ActoGeniX is progressing its preclinical product pipeline through preclinical development towards IND-ready stage. Positive efficacy data have been obtained in animal models for several disease areas. These areas include:

 

 

Notably, ActoGeniX has recently obtained efficacy data on the effect of an ActoBiotic™ expressing the anti-inflammatory cytokine IL-27 on colitis in an animal model. This groundbreaking work has been performed in collaboration with Professor Scott Durum at the National Cancer Institute (Frederick MD, US). ActoGeniX has also initiated testing of this product for its effect in a celiac disease model.